undamentalytics Newsletter
Sign in

Biomarin Pharmaceutical Inc cash flow statement

In fiscal 2025, Biomarin Pharmaceutical Inc's operations generated $828m of cash; it spent $103m on capital projects, leaving free cash flow of $725m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations88191818−60−70−219−228−9204885305176159573828857
Depreciation and amortisation21283544364647978896105105108102104968057
Stock-based pay363844476486112135140149160190197196207202181215
Capital spending9049734565117228148199145145114961219785103119
Free cash flow−2−31−55−27−125−187−447−376−208−124−97−292095563487725738
Free cash flow after stock pay−38−69−99−74−189−274−559−511−348−273−257−21912−141−145286544523
Share buybacks—————————005000————
Shares issued—00235011788871300————————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: BMRN vs BNTXBMRN vs UTHRBMRN vs NBIXARGX vs BMRN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Biomarin Pharmaceutical Inc's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Biomarin Pharmaceutical Inc.